玻璃体切割联合引流阀植入治疗伴玻璃体积血的新生血管性青光眼

目的:评价玻璃体切割联合引流阀植入治疗伴玻璃体积血的新生血管性青光眼的效果。方法:对30例(30眼)伴玻璃体积血的新生血管性青光眼患者采用玻璃体切割联合Ahmed青光眼引流阀植入术治疗,术后随访10~20(平均12)mo。结果:术后眼压控制在6.0~21.0mmHg25眼(其中3例需加用一种降眼压药物),3例眼压>21.0mmHg,2例长期低眼压,成功率83%。结论:玻璃体切割联合引流阀植入治疗伴玻璃体积血的新生血管性青光眼,术后成功率高,视力有所提高,并发症少。     

Ahmed青光眼阀植入联合玻璃体切割术治疗伴玻璃体积血的新生血管性青光眼

目的探讨Ahmed青光眼阀植入联合玻璃体切割术治疗伴有玻璃体积血的新生血管性青光眼的效果。方法回顾性分析22例(28只眼)患者因新生血管性青光眼伴有玻璃体积血接受玻璃体切割、Ahmed青光眼阀植入及全视网膜光凝。手术前视力光感～0.2,眼压平均44mmHg(38～63mmHg)(1mmHg=0.133kPa)。平均随访10个月(6～15个月)。结果手术后视力光感～0.3;眼压平均17mmHg(10～33mmHg),显著低于手术前眼压(P<0.05)。术后6,12,15个月的累积成功率分别为(85.1±3.2)%、(80.0±2.2)%、(65.0±4.1)%。手术后并发症主要包括一过性低眼压(4只眼),引流管堵塞(2只眼),玻璃体内再出血(2只眼),脉络膜上腔出血(1只眼),视网膜脱离(1只眼)。结论玻璃体切割联合Ahmed青光眼阀植入及全视网膜光凝术可能是治疗某些伴有玻璃体积血的新生血管性青光眼的有效方法。     

Ahmed青光眼阀植入联合玻璃体切割术治疗伴玻璃体积血的新生血管性青光眼的临床观察

目的探讨Ahm ed青光眼阀植入联合玻璃体切割术治疗伴有玻璃体积血新生血管性青光眼的效果。方法回顾性分析48例(52只眼)因新生血管性青光眼伴有玻璃体积血接受玻璃体切割及联合白内障摘除、全视网膜光凝及Ahm ed青光眼阀植入患者的病例资料。手术前视力光感~0.3,眼压平均42mmHg(38~65mmHg)(1mmHg=0.133kPa),平均随访10个月(6~15个月)。结果手术后视力光感~0.3;眼压平均18mmHg(10~34mmHg),显著低于手术前眼压(P<0.05);并发症主要包括前房及玻璃体内炎性渗出(3只眼)、玻璃体内再出血(3只眼)、术后一过性低眼压(5只眼)、1~2周内高眼压(4只眼)、手术后脉络膜上腔出血(2只眼)、视网膜脱离(1只眼)。结论玻璃体切割联合白内障摘除、全视网膜光凝及Ahm ed青光眼阀植入术可能是治疗某些新生血管性青光眼伴有玻璃体积血的有效方法.     

Ahmed青光眼阀植入治疗新生血管性青光眼

目的探讨Ahmed青光眼阀植入治疗新生血管性青光眼的有效性和安全性。方法采用Ahmed青光眼阀治疗新生血管性青光眼32例(32眼)。为视网膜血管性疾病及糖尿病所致的新生血管性青光眼。疗效评价:术后眼压8~21 mmHg,视功能保持或有改善为治愈。术后平均随访14月。结果手术成功率为71.87%,眼压从术前(54.32±15.48)mmHg下降为术后(19.55±5.76)mmHg。主要并发症有:早期低眼压、前房延缓形成、前房导管口阻塞、前房积血。结论Ahmed青光眼阀治疗新生血管性青光眼是一种有效的手术方法。     

Ahmed青光眼阀植入术联合前部玻璃体切除治疗新生血管性青光眼

目的:观察Ahmed青光眼阀(ahmed glaucoma valve,AGV)植入术联合前部玻璃体切除治疗新生血管性青光眼的疗效。方法:对观察组32例32眼新生血管性青光眼患者行AGV植入术联合前部玻璃体切除,观察术后浅前房等早期并发症的发生率及手术效果,并与对照组22例24眼按常规方法行AGV植入术者进行比较。结果:术后前房延缓形成的发生率:观察组为3/32(9.4%),对照组为8/24(33.3%),两组差异有统计学意义(χ2=4.987,P=0.026),术后早期低眼压:观察组为10/32(31.3%),对照组为14/24(58.3%),两组差异有统计学意义(χ2=4.108,P=0.043),引流管阻塞发生率两组差异均无统计学意义。所有病例术后1mo时眼压≤2.8kPa者:对照组15/24(62.5%),观察组28/32(87.5%)。随访6mo,观察组总成功率17/32(53.1%),对照组总成功率13/24(54.2%),两组差异无统计学意义。结论:AGV植入术联合前部玻璃体切除治疗新生血管性青光眼操作简单,并发症少,疗效满意,是值得推荐的治疗方法。     

玻璃体腔注射Bevacizumab联合Ahmed青光眼阀植入治疗新生血管性青光眼

目的 观察玻璃体腔注射Bevacizumab联合Ahmed青光眼阀植入治疗新生血管性青光眼(NVG)的术后疗效和并发症.方法 回顾性临床病例对照研究.选择新乡医学院第一附属医院眼科在2007年至2008年2月间接受过玻璃体腔注射Bevacizumab 0.05 mL/1.25 mg和Ahmed青光眼阀植入术的NVG患者...     

Ahmed青光眼阀植入术治疗新生血管性青光眼

目的:探讨Ahmed青光眼引流阀植入术治疗新生血管性青光眼的疗效及其并发症的防治。方法:回顾性分析18例18眼新生血管性青光眼行Ahmed青光眼阀植入术的疗效,主要观察指标为手术前后视力、眼压、并发症及手术成功率等,术后随访6~18mo。结果:术后最佳矫正视力不变11眼,提高5眼,下降2眼。术后眼压控制的有效率达到89%,术后并发症主要是早期的短暂性浅前房和高眼压、前房积血以及晚期的滤过道瘢痕纤维化。结论:Ahmed引流阀植入术是治疗新生血管性青光眼的一种比较有效的方法。     

Ahmed青光眼阀植入术治疗有视功能的新生血管性青光眼

目的：评价Ahmed青光眼阀植入术治疗有视功能的新生血管性青光眼的疗效及安全性。方法：对26例26眼有视功能的新生血管性青光眼施行颞上象限到赤道部区域的Ahmed表眼阀值入术,结果：术后经4－26mo（平均8mo)的随访观察,22例视力提高或不变,占86．4％,无1例因手术而失明;17眼眼压控制在0．8－2．8kPa,眼压控制率为65．4％,术后并发症包括;自顾不暇暂性前房出血,术后早期低眼压,引流管口阻塞及植入盘脱出,结论Ahmed青光眼阀植入术治疗有视功能的新生血管性青光眼旭一种有效且安全的方法。     

糖尿病新生血管性青光眼23G玻璃体视网膜手术

目的 探讨23G玻璃体视网膜手术治疗糖尿病性新生血管性青光眼的效果。方法 回顾性研究22例（22眼）糖尿病性新生血管性青光眼先作青光眼引流阀植入控制眼压,在1月内作23G玻璃体视网膜手术。术后随访6—12月,观察眼压变化。结果 16例手术后眼压在正常范围,4例需要加用降压药物控制,2例眼压未能控制。视力光感3例,手动2例,数指4例,0．05—0．1者7例,0．12～0．3者4例,0．4以上2例。术后复发性视网膜脱离3例;2例再次出现虹膜新生血管;前房积血7例,1—2周后吸收;取出硅油后再次玻璃体积血2例,行玻璃体腔冲洗及补充激光光凝;视神经萎缩2例;前部葡萄膜炎2例。结论 青光眼引流阀植入和23G玻璃体视网膜手术治疗糖尿病性新生血管性青光眼是一个较有效的治疗方法。     

Ahmed valve implantation for neovascular glaucoma after 23-gauge vitrectomy in eyes with proliferative diabetic retinopathy

AIM:To report on the outcome of Ahmed glaucoma valve (AGV) implantation for the management of neovascular glaucoma (NVG) after 23-gauge vitrectomy for proliferative diabetic retinopathy (PDR).METHODS: Twelve medically uncontrolled NVG with earlier 23-gauge vitrectomy for PDR underwent AGV implantation. The control of intraocular pressure (IOP), preoperative and postoperative best-corrected visual acuity, the development of intraoperative and postoperative complications were evaluated during the follow-up.RESULTS: The mean follow-up was 15.4±4.3 months (9-23 months). Mean preoperative IOP was 49.4±5.1mmHg and mean postoperative IOP at the last visit was 17.5±1.6mmHg. The control of IOP was achieved at the final follow-up visits in all patients, however, 8 of 12 patients still needed anti-glaucoma medication (mean number of medications, 0.8±0.7). The visual acuity improved in nine eyes, and the visual acuity unchanged in three eyes at the final follow-up visits. The complications that occurred were minor hyphema in three eyes, choroid detachment in two eyes, and the minor hyphema and choroid detachments were reabsorbed without any surgical intervention.CONCLUSION: AGV implantation is a safe and effective procedure that enables successful IOP control and vision preservation in the NVG patients with the history of earlier 23-gauge vitrectomy for PDR.     

Clinical efficacy of Ahmed glaucoma valve implantation combined with 23-gauge vitrectomy for medically uncontrolled neovascular glaucoma with proliferative diabetic retinopathy

AIM: To describe the clinical results of combined Ahmed valve implantation and 23-gauge vitrectomy for medically uncontrolled neovascular glaucoma (NVG) secondary to proliferative diabetic retinopathy (PDR). METHODS: The medical records of medically uncontrolled NVG patients with PDR who underwent Ahmed valve implantation and 23-gauge vitrectomy between March 2016 and December 2018 were reviewed. Enrolled patients had at least 6-month follow-up. Panretinal photocoagulation (PRP), anti-vascular endothelial growth factor, surgery and medication history were documented. RESULTS: Eleven eyes of 11 patients were included in our study. The visual acuity improved in 8 eyes and remained unchanged in 3 eyes. The preoperative intraocular pressure (IOP) was significantly decreased at the last follow-up (48.8±4.3 to 17.0±1.5 mm Hg, P<0.001). All eyes needed three topical anti-glaucomatous medications before surgery, but the number was significantly reduced to 0.72±0.19 at the last visit (P<0.001). Four eyes had choroidal detachment and 3 eyes had minor hyphemia, all of which gradually resolved without treatments in one week. CONCLUSION: Ahmed glaucoma valve implantation combined with 23-gauge vitrectomy might be a safe and alternative treatment for NVG with PDR.     

Pars plana Ahmed implantation combined with 23-gauge vitrectomy for refractory neovascular glaucoma in diabetic retinopathy

Purpose

To evaluate the efficacy and safety of a pars plana Ahmed valve implantation combined with 23-gauge sutureless vitrectomy in the treatment of patients with medically uncontrolled neovascular glaucoma (NVG) in proliferative diabetic retinopathy (PDR).

Methods

The authors retrospectively reviewed the records of 11 consecutive patients with refractory NVG in PDR who underwent a 23-gauge sutureless vitrectomy combined with pars plana placement of an Ahmed valve implant. Control of intraocular pressure (IOP), pre- and postoperative best-corrected visual acuity and the development of intra- and postoperative complications were evaluated during the follow-up.

Results

The mean follow-up was 12.2 months (range, 8 to 25 months). Mean preoperative IOP was 35.9 ± 6.3 mmHg and mean postoperative IOP at the last visit was 13.3 ± 3.2 mmHg. Control of IOP (8 to 18 mmHg) was achieved in all patients, but 91% (10 of 11 patients) needed antiglaucoma medication (mean number of medications, 1.2 ± 0.6). Postoperative visual acuity improved in 11 eyes, and the logarithmically to the minimum angle of resolution mean visual acuity in these eyes improved from 1.67 ± 0.61 to 0.96 ± 0.67. The complications that occurred were transient hypotony in one case, transitory hypertension in two cases, and postoperative vitreous hemorrhage which spontaneously cleared in two cases.

Conclusions

We suggest the combination of 23-gauge pars plana vitrectomy and Ahmed valve implantation is safe and effective in PDR patients with refractory NVG.     

Ahmed引流阀植入联合玻璃体腔注射Avastin治疗NVG

观察Ahmed阀植入联合玻璃体腔注射avastin治疗新生血管性青光眼(neovascular glaucoma, NVG)的疗效。 方法：对NVG患者20例20眼先行玻璃体腔注射avastin 0.1mL(2.5mg),待虹膜新生血管消退后行Ahmed青光眼引流阀植入术。术后观察视力、眼压、虹膜新生血管消退情况、术中及术后并发症,随访6～36(平均24)mo。 结果：玻璃体腔注射avastin后1wk内20眼虹膜新生血管均不同程度消退。Ahmed引流阀植入术后最后一次随访20眼中仅有3眼联合1～3种抗青光眼药物眼压≤21mmHg,1眼因眼压无法控制而行睫状体冷凝术（术后眼压控制）,其余16眼无需加用抗青光眼药物眼压控制在正常范围。最后一次随访,平均眼压13.62±3.81mmHg,与术前平均眼压（44.17±16.17mmHg）比较,差异有统计学意义(t=11.028,P=0.000)。视力提高者8眼（40％）,保持不变者12眼。全部病例在玻璃体腔注射avastin及Ahmed引流阀植入术中术后均未观察到严重手术并发症。 结论：Ahmed引流阀植入联合玻璃体腔注射avastin治疗NVG安全有效,手术成功率高,并发症少,有利于保护残留的视功能,但其长期疗效还需进一步观察,同时要注意原发病的处理。 关键词：新生血管性青光眼;Ahmed引流阀;玻璃体腔注射;avastin